Table 1.

Demographics and baseline characteristics of 472 patients with cirrhosis initiated on RRT for AKI

CharacteristicNot Listed for Liver TransplantListed for Liver Transplant
All Not ListedHRSATNAll ListedHRSATN
n=341n=56n=285n=131n=62n=69
Age, yr58 (57 to 59)57 (53 to 60)58 (57 to 60)55 (54 to 57)56 (54 to 59)54 (52 to 57)
Female sex111 (33)17 (30)94 (33)51 (39)26 (42)25 (36)
White race257 (75)40 (71)217 (76)112 (86)55 (89)57 (83)
Non-Hispanic ethnicity317 (93)53 (95)264 (93)124 (95)59 (95)65 (94)
Comorbidities
 Diabetes mellitus126 (37)20 (36)106 (37)44 (34)22 (36)22 (32)
 Coronary artery disease98 (29)17 (30)81 (28)28 (21)14 (23)14 (20)
 CKD54 (16)18 (32)36 (13)25 (19)12 (19)13 (19)
 Hypertension187 (55)32 (57)155 (54)76 (58)41 (66)35 (51)
Reason for admission
 Complications of cirrhosis96 (28)28 (50)68 (24)75 (57)41 (66)34 (49)
 AKI43 (13)15 (27)28 (10)23 (18)15 (24)8 (12)
 Infection126 (37)8 (14)118 (41)23 (18)4 (6)19 (28)
 Other76 (22)5 (9)71 (25)10 (8)2 (3)8 (12)
Other hospitalization characteristics
 Sepsis206 (60)17 (30)189 (66)73 (56)27 (44)46 (67)
 Admission/transfer to intensive care unit287 (85)34 (61)253 (89)99 (76)41 (66)58 (84)
 Intravenous vasopressor use260 (76)28 (50)232 (81)91 (69)35 (56)56 (81)
 Mechanical ventilation197 (58)9 (16)188 (66)54 (41)19 (31)35 (51)
 Length of stay, d21 (19 to 23)18 (14 to 23)21 (18 to 24)35 (30 to 39)33 (26 to 39)36 (29 to 43)
Initial renal replacement modality
 Intermittent hemodialysis195 (57)41 (73)154 (54)76 (58)39 (63)37 (54)
 Continuous veno-venous hemofiltration146 (43)15 (27)131 (46)55 (42)23 (37)32 (46)
Cause of cirrhosisa
 Alcohol135 (40)24 (45)111 (39)40 (31)23 (37)17 (25)
 Hepatitis C59 (17)7 (13)52 (18)27 (21)12 (19)15 (22)
 Nonalcoholic steatohepatitis21 (6)5 (9)16 (6)20 (15)10 (16)10 (14)
 Multifactorial45 (13)9 (16)36 (13)14 (11)6 (10)8 (12)
 Other79 (23)10 (18)69 (24)30 (23)11 (17)19 (28)
Prior complications of liver disease
 Ascites263 (77)53 (95)210 (74)124 (95)62 (100)62 (90)
 Encephalopathy186 (55)36 (64)150 (53)93 (71)49 (79)44 (64)
 Gastrointestinal bleeding215 (63)39 (70)176 (62)86 (66)44 (71)42 (61)
 Spontaneous bacterial peritonitis61 (18)9 (16)52 (18)53 (40)30 (48)23 (33)
 Hepatocellular carcinoma29 (9)8 (14)21 (7)12 (9)4 (6)8 (12)
MELD score34 (33 to 34)36 (34 to 38)33 (32 to 34)36 (35 to 37)37 (35 to 38)35 (33 to 37)
CLIF-C ACLF score60 (59 to 62)50 (47 to 53)62 (60 to 63)58 (56 to 60)55 (52 to 58)59 (56 to 63)
Laboratory values
 Sodium, meq/L136 (135 to 136)134 (133 to 136)136 (135 to 137)135 (134 to 136)135 (133 to 136)135 (134 to 137)
 BUN, mg/dl65 (61 to 69)61 (53 to 68)66 (61 to 70)65 (60 to 70)70 (63 to 77)61 (54 to 68)
 Creatinine, mg/dl4.3 (4.1 to 4.5)5.3 (4.9 to 5.8)4.1 (3.9 to 4.4)4.1 (3.9 to 4.4)4.6 (4.2 to 4.9)3.8 (3.4 to 4.2)
 Urine sodium, mmol/Lb36 (29 to 42)33 (1 to 66)36 (32 to 40)24 (19 to 29)20 (14 to 25)29 (21 to 36)
 White blood count, K/μl14.8 (13.7 to 15.9)10.5 (8.7 to 12.3)15.6 (14.4 to 16.9)10.4 (9.2 to 11.6)9.6 (8.3 to 10.9)11.1 (9.1 to 13.2)
 Hemoglobin, g/dl9.3 (9.2 to 9.5)9.4 (8.9 to 9.9)9.3 (9.1 to 9.5)9.0 (8.7 to 9.2)9.0 (8.6 to 9.3)9.0 (8.6 to 9.3)
 Platelets, K/μl102 (95 to 110)88 (72 to 104)105 (97 to 113)76 (68 to 85)72 (61 to 83)80 (67 to 93)
 Albumin, g/dlc2.9 (2.8 to 3.0)3.2 (3.1 to 3.4)2.8 (2.8 to 2.9)3.3 (3.2 to 3.4)3.4 (3.2 to 3.5)3.2 (3.0 to 3.4)
 International normalized ratio2.1 (2.0 to 2.2)2.0 (1.8 to 2.3)2.1 (2.0 to 2.2)2.2 (2.1 to 2.3)2.1 (2.0 to 2.3)2.2 (2.0 to 2.4)
 Total bilirubin, mg/dl12 (10 to 13)14 (10 to 19)11 (10 to 13)16 (13 to 18)16 (12 to 20)16 (13 to 19)
 Aspartate aminotransferase, U/Ld577 (390 to 764)452 (−20 to 924)602 (397 to 807)254 (−20 to 528)101 (46 to 156)391 (−130 to 913)
 Alanine aminotransferase, U/Ld189 (137 to 241)177 (11 to 344)192 (139 to 244)120 (−8 to 250)40 (29 to 52)191 (−54 to 436)
 Alkaline phosphatase, U/Ld162 (145 to 178)146 (112 to 181)165 (146 to 183)114 (102 to 126)113 (97 to 130)116 (98 to 133)
  • Cells represent N (percent) for categoric variables and mean (95% confidence interval) for continuous variables. HRS, hepatorenal syndrome; ATN, acute tubular necrosis; MELD, Model for End Stage Liver Disease; CLIF-C ACLF, Chronic Liver Failure Consortium Acute-on-Chronic Liver Failure Score.

  • a n=470 available.

  • b n=357 available.

  • c n=471 available.

  • d n=468 available.